MRI of hypertrophic cardiomyopathy: Part 2, differential diagnosis, risk stratification, and posttreatment MRI appearances

American Journal of Roentgenology

Volumn 189, Issue 6, 2007, Pages 1344-1352

  Hansen, Mark W ^a,b   Merchant, Naeem ^b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cardiac imaging; Cardiomyopathy; Cardiovascular imaging; Fabry's disease; Hypertrophic cardiomyopathy; MRI; Sarcoidosis; Sports medicine

Indexed keywords

AMYLOID; GADOLINIUM; GALLIUM 67; THALLIUM 201;

AORTA STENOSIS; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; FABRY DISEASE; HEART AMYLOIDOSIS; HEART SCINTISCANNING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOMECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 36448985230     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2287     Document Type: Review

References (55)

1. Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part 1, MRI appearances. AJR 2007; 189:1335-1343
2. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363:1881-1891
3. Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology 2004; 44:412-427
4. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998; 136:824-830
5. Prasad K, Atherton J, Smith GC, McKenna WJ, Frenneaux MP, Nihoyannopoulos P. Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart 1999; 82[suppl 3]:III8-III15
6. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111:186-193
7. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26:1461-1474
8. Beckerman J, Wang P, Hlatky M. Cardiovascular screening of athletes. Clin J Sport Med 2004; 14:127-133
9. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349:1064-1075
10. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete's heart in women: echocardiographic characterization of highly trained elite female athletes. JAMA 1996; 276:211-215
11. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002; 105:944-949
12. Petersen SE, Selvanayagam JB, Francis JM, et al. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005; 7:551-558
13. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407-1411
14. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110:1047-1053
15. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986; 7:1157-1161
16. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139:1101-1108
17. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24:2151-2155
18. Sperling RT, Parker JA, Manning WJ, Danias PG. Apical hypertrophic cardiomyopathy: clinical, electrocardiographic, scintigraphic, echocardiographic, and magnetic resonance imaging findings of a case. J Cardiovasc Magn Reson 2002; 4:291-295
19. Dijkmans PA, Visser CA, Kamp O. An abnormal ECG with inverted T waves in the precordial leads; confirming the diagnosis with contrast enhanced echocardiography. Heart 2005; 91:913
20. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128:79-85
21. Andy JJ. Aetiology of endomyocardial fibrosis (EMF). West Afr J Med 2001; 20:199-207
22. Felice PV, Sawicki J, Anto J. Endomyocardial disease and eosinophilia. Angiology 1993; 44:869-874
23. Hassan WM, Fawzy ME, Al Helaly S, Hegazy H, Malik S. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest 2005; 128:3985-3992
24. Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. Australas Radiol 2001; 45:524-527
25. Mayet J, Kanagaratnam P, Lincoln C, Oldershaw P. Hypereosinophilic syndrome: endomyocardial fibrosis. Heart 1997; 77:391
26. Pitt M, Davies MK, Brady AJ. Hypereosinophilic syndrome: endomyocardial fibrosis. Heart 1996; 76:377-378
27. Salanitri GC. Endomyocardial fibrosis and intracardiac thrombus occurring in idiopathic hypereosinophilic syndrome. AJR 2005; 184:1432-1433
28. Alter P, Maisch B. Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging. Int J Cardiol 2006; 108:112-113
29. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58:1204-1211
30. Stauder NI, Bader B, Fenchel M, Kramer U, Kühlkamp V, Miller S. Images in cardiovascular medicine: follow-up of cardiac sarcoidosis by magnetic resonance imaging. Circulation 2005; 111:e158-e160
31. Sharma OP. Cardiac and neurologic dysfunction in sarcoidosis. Clin Chest Med 1997; 18:813-825
32. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR 2005; 184:249-254
33. Dubrey SW, Grocott-Mason R, Mittal TK. Images in cardiology: cardiac sarcoidosis with delayed enhanced MRI. Heart 2005; 91:1185
34. Kiuchi S, Teraoka K, Koizumi K, Takazawa K, Yamashita A. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging 2007; 23:237-241
35. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45:1683-1690
36. Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR 2005; 185:110-115
37. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42:1687-1713
38. Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004; 22:155-161 [Erratum in Magn Reson Imaging 2004; 22:901]
39. Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005; 91:1036-1040
40. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41:1561-1567
41. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420-424
42. Kovacic JC, Muller D. Hypertrophic cardiomyopathy: state-of-the-art review, with focus on the management of outflow obstruction. Intern Med J 2003; 33:521-529
43. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:470-476
44. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005; 111:2033-2041
45. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98:2415-2421
46. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38:1701-1706
47. Amano Y, Takayama M, Amano M, Kumazaki T. MRI of cardiac morphology and function after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. AJR 2004; 182:523-527
48. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG. The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 2000; 101:1764-1766
49. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003; 42:296-300
50. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103:1492-1496
51. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005; 129:351-358
52. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999; 20:1342-1354
53. Lawrenz T, Obergassel L, Lieder F, et al. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005; 28:295-300
54. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38:315-321
55. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338:1248-1257